BC Extra | Aug 6, 2019
Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

Alnylam's Onpattro bests consensus  Sales of amyloidosis therapy Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reached $38.2 million in 2Q19, the drug's third full quarter on the market. The figure beat analysts' consensus of $32...
BC Week In Review | Jan 5, 2018
Company News

Angiochem grants Xinogen Chinese rights to ANG1005

Angiochem Inc. (Montreal, Quebec) granted Xinogen Hong Kong Pharma Co. Ltd. exclusive, Chinese rights to develop and commercialize ANG1005 to treat leptomeningeal carcinomatosis and brain metastases arising from metastatic breast cancer. The therapy is a...
BC Extra | Jan 3, 2018
Company News

Angiochem, Xinogen in China deal

Angiochem Inc. (Montreal, Quebec) granted an exclusive license in China to Xinogen Hong Kong Pharma Co. Ltd. to develop and commercialize ANG1005 to treat leptomeningeal carcinomatosis and brain metastases arising from metastatic breast cancer. The...
BC Week In Review | Dec 7, 2015
Clinical News

ANG1005: Interim Phase II data

Interim data from 21 heavily pre-treated breast cancer patients with leptomeningeal carcinomatosis in an open-label, U.S. Phase II trial showed that ANG1005 led to 5 partial responses and 11 cases of stable disease as best...
BC Week In Review | Jun 9, 2014
Clinical News

ANG1005: Phase II started

Angiochem began an open-label, U.S. Phase II trial to evaluate ANG1005 in up to 40 patients with progressive or recurrent HER2-positive breast cancer with brain metastases. Late last month, FDA granted Orphan Drug and Fast...
BC Week In Review | Oct 28, 2013
Clinical News

ANG1005: Phase II started

Angiochem began a U.S. Phase II trial to evaluate ANG1005 in up to 83 patients with recurrent high-grade glioma. Next quarter, Angiochem also plans to start a Phase II trial of ANG1005 in HER2-positive breast...
BC Week In Review | Oct 28, 2013
Clinical News

ANG1005: Additional Phase II data

Angiochem said it will continue to develop ANG1005 based on data from 80 patients with brain metastases arising from metastatic breast cancer in the open-label, North American Phase II GRABM-B trial showing that the compound...
BC Extra | Oct 21, 2013
Company News

Angiochem advances ANG1005 for cancer

Angiochem Inc. (Montreal, Quebec) said it will continue to develop ANG1005 (formerly GRN1005 ) based on additional Phase II data showing the compound produced responses in breast cancer patients with brain metastases. Last year, Geron Corp....
BioCentury | Jan 7, 2013
Finance

4Q Stock Wrap-Up: Go big or go home

Large cap biotechs were the only market cap segment to end 4Q12 in the black, finishing up 1% to post a 26% gain on the year. Small caps brought up the rear in 4Q, but...
BC Week In Review | Dec 10, 2012
Clinical News

GRN1005: Development discontinued

Geron discontinued development of GRN1005 after a planned interim futility analysis of the first 30 evaluable patients with brain metastases arising from metastatic breast cancer in the open-label, North American Phase II GRABM-B trial showed...
Items per page:
1 - 10 of 45